PATENT CLAIM ANALYSIS

Application Number: 16009751
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "161000"]

Abstract:
The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with at least one symptom of the common cold. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof.

Claim (Index 14):
A method of inhibiting the symptoms associated with the common cold, comprising:\n administering to a subject an effective amount of a pharmaceutical composition prior to appearance of a common cold symptom, wherein the pharmaceutical composition consists essentially of: a) about 220 mg to about 880 mg of naproxen sodium, and about 60 mg to about 180 mg fexofenadine, wherein the symptoms associated with the common cold are inhibited.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 94.0
- Lexical Diversity: 1.55102
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15074524', '14699676', '11172878', '10363430', '13503097']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7469604056867718
- 35 USC 102 Novelty (BERT): 0.4975576038507969
- Combined Prediction Score: 0.7220201255031743
- Mean Citation Score: 211.190474
- Max Citation Score: 239.92516
- Similarity Product: 172.7214105343151

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test